Related Experiment Video
Updated: Feb 28, 2026
Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
Published on: January 31, 2025
Extracellular Vesicles as Biomarkers and Non-Surgical Therapeutics in Cardiovascular Diseases
Dana A Almazroua1, Kelsey C Muir2, M Ruhul Abid2
1College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
Insights
Extracellular vesicles (EVs) show promise as non-invasive biomarkers and cell-free therapeutics for cardiovascular diseases (CVD). Further research is needed to overcome challenges for clinical translation in managing heart conditions.
Area of Science:
- Cardiovascular Research
- Biotechnology
- Regenerative Medicine
Background:
- Cardiovascular disease (CVD) is a leading cause of mortality, with current treatments for myocardial ischemia being invasive.
- Extracellular vesicles (EVs) are increasingly recognized for their role in cardiovascular pathophysiology.
- There is a critical need for improved non-invasive diagnostic and therapeutic strategies for CVD.
Purpose of the Study:
- To review the current literature on extracellular vesicle (EV) biology and their applications in cardiovascular medicine.
- To analyze the potential of EVs as biomarkers and therapeutics for various cardiovascular conditions.
- To identify existing gaps and challenges in the clinical translation of EV-based approaches.
Main Methods:
- Synthesis of preclinical and clinical literature on EV classification, isolation, and characterization.
- Analysis of studies evaluating EVs for intercellular communication mechanisms.
- Critical review of research on EVs as biomarkers and non-surgical therapeutics in cardiovascular diseases.
Main Results:
- EVs mediate intercellular communication by transferring bioactive molecules, influencing disease and repair.
- Evidence supports EVs as potential biomarkers for predicting cardiovascular disease risk and severity.
- EVs show promise as cell-free therapeutics for myocardial infarction, cardiomyopathies, atrial fibrillation, and heart failure.
Conclusions:
- Extracellular vesicles (EVs) offer a promising avenue for non-invasive cardiovascular diagnostics and therapeutics.
- Methodological inconsistencies, lack of validated biomarkers, and translation barriers must be addressed.
- Advancements in EV bioengineering are crucial for realizing their full clinical potential in managing CVD.
Abstract:
Background: Cardiovascular disease (CVD), including myocardial ischemia, remains the leading cause of mortality. Current therapies for ischemic myocardium rely largely on invasive revascularization strategies, highlighting the need for improved non-invasive diagnostic and therapeutic approaches. Recent studies suggest that extracellular vesicles (EVs) play a critical role in cardiovascular pathophysiology and may offer novel clinical applications. Methods: This review synthesizes current preclinical and clinical literature on EV biology, including their classification, isolation, and characterization methods, and mechanisms of Intercellular communication. Published studies evaluating EVs as biomarkers and non-surgical therapeutics across major cardiovascular conditions were critically analyzed. Results: EVs facilitate intercellular communication by transferring bioactive molecules that influence disease progression and cardiac repair. Accumulating evidence supports their potential utility as biomarkers for disease prediction and severity assessment, as well as cell-free therapeutics in myocardial infarction, cardiomyopathies, atrial fibrillation, and heart failure. However, significant gaps remain, including the lack of validated EV-based biomarkers, inconsistent isolation and characterization methodologies, limited in vivo tracking data, and barriers to clinical translation. Conclusions: EVs represent a promising frontier in non-invasive cardiovascular diagnostics and therapeutics. Addressing current methodological and translational challenges, alongside advances in EV bioengineering, will be essential to realize their full clinical potential in CVD management.
